▲ +372.73% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $7.80, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 372.73% upside from the last price of $1.65.
The current consensus among 5 contributing investment analysts is to buy stock in ADMA Biologics. This Buy consensus rating has held steady for over two years.
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.